Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.52 |
| ▸ | RET | P07949 | 5/20 | 0.43 |
| ▸ | SPR | P35270 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 5/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291332 | 0.93 | JAK3 (0.47) | JAK3RETNAMPTGPR119 | |
| SCHEMBL30558296 | 0.88 | JAK3 (0.46) | JAK3RETGPR119 | |
| SCHEMBL20839065 | 0.88 | JAK3 (0.46) | JAK3RETGPR119 | |
| SCHEMBL18291330 | 0.82 | EIF2AK4 (0.45) | RETNAMPT | |
| SCHEMBL30664043 | 0.80 | CYP3A4 (0.47) | NAMPTGPR119 | |
| SCHEMBL18291310 | 0.80 | CYP3A4 (0.47) | NAMPTGPR119 | |
| SCHEMBL30419374 | 0.80 | NR1H2 (0.42) | JAK3GPR119 | |
| SCHEMBL1990092 | 0.80 | NR1H2 (0.42) | JAK3GPR119 | |
| SCHEMBL18291717 | 0.80 | CDK4 (0.50) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL18291321 | 0.79 | CYP11B2 (0.51) | SPRNAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | JAK3 50/4885RET 577/4885SPR 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.